#Biktarvy

Gilead Sciences has released 96-week results from an ongoing double-blinded study comparing the two regimens.

The new single-tablet antiretroviral regimen includes the integrase inhibitor bictegravir and is the smallest such tablet on the market.

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

The investigational integrase inhibitor bictegravir appears to have a resistance profile superior to currently available drugs in its class.